This Article  • Full text  • PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (158)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Tobacco  • Randomized Controlled Trial  • Alert me on articles by topic

Efficacy of Varenicline, an 42 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation

A Randomized Controlled Trial

Douglas E. Jorenby, PhD; J. Taylor Hays, MD; Nancy A. Rigotti, MD; Salomon Azoulay, MD; Eric J. Watsky, MD; Kathryn E. Williams, PhD; Clare B. Billing, MS; Jason Gong, MD; Karen R. Reeves, MD; for the Varenicline Phase 3 Study Group

JAMA. 2006;296:56-63.

Context  Varenicline, a partial agonist at the 42 nicotinic acetylcholine receptor, has the potential to aid smoking cessation by relieving nicotine withdrawal symptoms and reducing the rewarding properties of nicotine.

Objective  To determine the efficacy and safety of varenicline for smoking cessation compared with placebo or sustained-release bupropion (bupropion SR).

Design, Setting, and Participants  A randomized, double-blind, placebo-controlled trial conducted between June 2003 and March 2005 at 14 research centers with a 12-week treatment period and follow-up of smoking status to week 52. Of 1413 adult smokers who volunteered for the study, 1027 were enrolled; 65% of randomized participants completed the study.

Intervention  Varenicline titrated to 1 mg twice daily (n = 344) or bupropion SR titrated to 150 mg twice daily (n = 342) or placebo (n = 341) for 12 weeks, plus weekly brief smoking cessation counseling.

Main Outcome Measures  Continuous abstinence from smoking during the last 4 weeks of treatment (weeks 9-12; primary end point) and through the follow-up period (weeks 9-24 and 9-52).

Results  During the last 4 weeks of treatment (weeks 9-12), 43.9% of participants in the varenicline group were continuously abstinent from smoking compared with 17.6% in the placebo group (odds ratio [OR], 3.85; 95% confidence interval [CI], 2.69-5.50; P<.001) and 29.8% in the bupropion SR group (OR, 1.90; 95% CI, 1.38-2.62; P<.001). For weeks 9 through 24, 29.7% of participants in the varenicline group were continuously abstinent compared with 13.2% in the placebo group (OR, 2.83; 95% CI, 1.91-4.19; P<.001) and 20.2% in the bupropion group (OR, 1.69; 95% CI, 1.19-2.42; P = .003). For weeks 9 through 52, 23% of participants in the varenicline group were continuously abstinent compared with 10.3% in the placebo group (OR, 2.66; 95% CI, 1.72-4.11; P<.001) and 14.6% in the bupropion SR group (OR, 1.77; 95% CI, 1.19-2.63; P = .004). Treatment was discontinued due to adverse events by 10.5% of participants in the varenicline group, 12.6% in the bupropion SR group, and 7.3% in the placebo group. The most common adverse event with varenicline was nausea, which occurred in 101 participants (29.4%).

Conclusions  Varenicline is an efficacious, safe, and well-tolerated smoking cessation pharmacotherapy. Varenicline's short-term and long-term efficacy exceeded that of both placebo and bupropion SR.

Trial Registration  clinicaltrials.gov Identifier: NCT00143364

Author Affiliations: University of Wisconsin School of Medicine and Public Health, Center for Tobacco Research and Intervention, Madison, Wis (Dr Jorenby); Division of General Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minn (Dr Hays); Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Mass (Dr Rigotti); and Pfizer Global Research and Development, Groton, Conn (Drs Azoulay, Watsky, Williams, Gong, and Reeves and Mr Billing).

RELATED ARTICLES

Varenicline, an 42 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation: A Randomized Controlled Trial
David Gonzales, Stephen I. Rennard, Mitchell Nides, Cheryl Oncken, Salomon Azoulay, Clare B. Billing, Eric J. Watsky, Jason Gong, Kathryn E. Williams, Karen R. Reeves, and for the Varenicline Phase 3 Study Group
JAMA. 2006;296(1):47-55.
ABSTRACT | FULL TEXT  

Effect of Maintenance Therapy With Varenicline on Smoking Cessation: A Randomized Controlled Trial
Serena Tonstad, Philip Tønnesen, Peter Hajek, Kathryn E. Williams, Clare B. Billing, Karen R. Reeves, and for the Varenicline Phase 3 Study Group
JAMA. 2006;296(1):64-71.
ABSTRACT | FULL TEXT  

Varenicline for Smoking Cessation: Definite Promise, But No Panacea
Robert C. Klesges, Karen C. Johnson, and Grant Somes
JAMA. 2006;296(1):94-95.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Varenicline for Tobacco Dependence
Hays and Ebbert
NEJM 2008;359:2018-2024.
FULL TEXT  

Review: Pharmacotherapy for smoking cessation
Carrozzi et al.
Therapeutic Advances in Respiratory Disease 2008;2:301-317.
ABSTRACT  

Neuropsychiatric disturbance after initiation of varenicline in a patient with a history of alcohol abuse and major depression
Pirmoradi et al.
Am J Health Syst Pharm 2008;65:1624-1626.
ABSTRACT | FULL TEXT  

The place of varenicline in smoking cessation treatment
Aveyard
Thorax 2008;63:666-668.
FULL TEXT  

Influence of Neuronal Nicotinic Receptors over Nicotine Addiction and Withdrawal
De Biasi and Salas
Exp. Biol. Med. 2008;233:917-929.
ABSTRACT | FULL TEXT  

Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial
Aubin et al.
Thorax 2008;63:717-724.
ABSTRACT | FULL TEXT  

Smoking: A Deadly Pleasant Habit--Is There a Way Out?
Richter
ANGIOLOGY 2008;59:49S-53S.
ABSTRACT  

Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials
Eisenberg et al.
CMAJ 2008;179:135-144.
ABSTRACT | FULL TEXT  

Prevention Strategies for Cardiovascular Disease in HIV-Infected Patients
Stein et al.
Circulation 2008;118:e54-e60.
FULL TEXT  

Update on pharmacologic and nonpharmacologic therapies for smoking cessation
Schmelzle et al.
cfp 2008;54:994-999.
ABSTRACT | FULL TEXT  

Diffuse exanthema in a patient receiving varenicline
Song and Miller
Am J Health Syst Pharm 2008;65:1239-1241.
ABSTRACT | FULL TEXT  

Positive Modulation of GABAB Receptors Decreased Nicotine Self-Administration and Counteracted Nicotine-Induced Enhancement of Brain Reward Function in Rats
Paterson et al.
J. Pharmacol. Exp. Ther. 2008;326:306-314.
ABSTRACT | FULL TEXT  

{blacktriangledown}Varenicline for smoking cessation
DTB 2008;46:33-36.
ABSTRACT | FULL TEXT  

Drugs (including oxygen) in severe COPD
Albert and Calverley
Eur Respir J 2008;31:1114-1124.
ABSTRACT | FULL TEXT  

Multidisciplinary Care of the Patient with Chronic Obstructive Pulmonary Disease
Kuzma et al.
Proc Am Thorac Soc 2008;5:567-571.
ABSTRACT | FULL TEXT  

How to implement a smoke-free policy
Cormac and McNally
Adv. Psychiatr. Treat. 2008;14:198-207.
ABSTRACT | FULL TEXT  

Differential Role of Nicotinic Acetylcholine Receptor Subunits in Physical and Affective Nicotine Withdrawal Signs
Jackson et al.
J. Pharmacol. Exp. Ther. 2008;325:302-312.
ABSTRACT | FULL TEXT  

Commentary on "Limb Ischemia: Medical Therapy Trial Update"
Henke
PERSPECT VASC SURG ENDOVASC THER 2008;20:43-44.
 

Management of Cardiovascular Disease in Renal Transplant Recipients
Shirali and Bia
CJASN 2008;3:491-504.
ABSTRACT | FULL TEXT  

The effectiveness and cost effectiveness of telephone counselling and the nicotine patch in a state tobacco quitline
Hollis et al.
Tobacco Control 2007;16:i53-i59.
ABSTRACT | FULL TEXT  

Pharmacologic Therapy: Novel Approaches for Chronic Obstructive Pulmonary Disease
Bailey and Tashkin
Proc Am Thorac Soc 2007;4:543-548.
ABSTRACT | FULL TEXT  

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary
Rabe et al.
Am. J. Respir. Crit. Care Med. 2007;176:532-555.
ABSTRACT | FULL TEXT  

A Double-blind, Placebo-Controlled, Randomized Trial of Bupropion for Smoking Cessation in Primary Care
Fossati et al.
Arch Intern Med 2007;167:1791-1797.
ABSTRACT | FULL TEXT  

Lung Cancer Chemoprevention: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition)
Gray et al.
Chest 2007;132:56S-68S.
ABSTRACT | FULL TEXT  

ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine
Anderson et al.
J Am Coll Cardiol 2007;50:e1-e157.
FULL TEXT  

ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine
Anderson et al.
J Am Coll Cardiol 2007;50:652-726.
FULL TEXT  

Varenicline, an {alpha}4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking
Steensland et al.
Proc. Natl. Acad. Sci. USA 2007;104:12518-12523.
ABSTRACT | FULL TEXT  

Update in General Internal Medicine
Harrington and Munekata
ANN INTERN MED 2007;147:104-116.
FULL TEXT  

Varenicline: The newest agent for smoking cessation
Potts and Garwood
Am J Health Syst Pharm 2007;64:1381-1384.
ABSTRACT | FULL TEXT  

Update in Chronic Obstructive Pulmonary Disease 2006
Rabe et al.
Am. J. Respir. Crit. Care Med. 2007;175:1222-1232.
FULL TEXT  

State of the Art Reviews: Smoking Cessation: A Review of Treatment Considerations
Sullivan et al.
AMERICAN JOURNAL OF LIFESTYLE MEDICINE 2007;1:201-213.
ABSTRACT  

Alcohol history and smoking cessation in nicotine replacement therapy, bupropion sustained release and varenicline trials: a review
Leeman et al.
Alcohol Alcohol 2007;42:196-206.
ABSTRACT | FULL TEXT  

Update in Lung Cancer 2006
Dubey and Powell
Am. J. Respir. Crit. Care Med. 2007;175:868-874.
FULL TEXT  

The Year in Atherothrombosis
Sanz et al.
J Am Coll Cardiol 2007;49:1740-1749.
FULL TEXT  

Comment: Oral Varenicline for Smoking Cessation
Gonzales et al.
The Annals of Pharmacotherapy 2007;41:720-721.
FULL TEXT  

Ca2+ Permeability of the ({alpha}4)3(beta2)2 Stoichiometry Greatly Exceeds That of ({alpha}4)2(beta2)3 Human Acetylcholine Receptors
Tapia et al.
Mol. Pharmacol. 2007;71:769-776.
ABSTRACT | FULL TEXT  

Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy
Tonnesen et al.
Eur Respir J 2007;29:390-417.
ABSTRACT | FULL TEXT  

A research agenda for assessing the potential contribution of genomic medicine to tobacco control
Hall
Tobacco Control 2007;16:53-58.
ABSTRACT | FULL TEXT  

Varenicline (Chantix) for Tobacco Dependence
Obstet Gynecol 2007;109:192-193.
FULL TEXT  

Oral Varenicline for Smoking Cessation
Zierler-Brown and Kyle
The Annals of Pharmacotherapy 2007;41:95-99.
ABSTRACT | FULL TEXT  

Efficacy of Varenicline for Smoking Cessation
Dervaux et al.
JAMA 2006;296:2555-2555.
FULL TEXT  

Efficacy of Varenicline for Smoking Cessation--Reply
Jorenby et al.
JAMA 2006;296:2555-2556.
FULL TEXT  

Trials that Matter: Varenicline: A Designer Drug to Help Smokers Quit.
Schroeder and Sox
ANN INTERN MED 2006;145:784-785.
FULL TEXT  

Promising New Drug Could Help Smokers Kick the Habit
Holman
DOC News 2006;3:16-16.
FULL TEXT  

Smoking Cessation With Varenicline, a Selective {alpha}4beta2 Nicotinic Receptor Partial Agonist: Results From a 7-Week, Randomized, Placebo- and Bupropion-Controlled Trial With 1-Year Follow-up.
Nides et al.
Arch Intern Med 2006;166:1561-1568.
ABSTRACT | FULL TEXT  

Is a New Smoking-Cessation Drug on the Horizon?
Journal Watch Cardiology 2006;2006:5-5.
FULL TEXT  

New Drug for Smoking Cessation
JWatch General 2006;2006:2-2.
FULL TEXT  

Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.
Gonzales et al.
JAMA 2006;296:47-55.
ABSTRACT | FULL TEXT  

Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial.
Tonstad et al.
JAMA 2006;296:64-71.
ABSTRACT | FULL TEXT  

Varenicline for smoking cessation: definite promise, but no panacea.
Klesges et al.
JAMA 2006;296:94-95.
FULL TEXT